Catalent (CTLT) Stock Rating Lowered by Zacks Investment Research
Zacks Investment Research cut shares of Catalent (NYSE:CTLT) from a buy rating to a hold rating in a report released on Thursday.
According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
Other equities analysts have also recently issued research reports about the stock. ValuEngine raised shares of Catalent from a hold rating to a buy rating in a research note on Monday, November 12th. Royal Bank of Canada set a $44.00 target price on shares of Catalent and gave the company a buy rating in a research note on Wednesday, November 7th. Morgan Stanley set a $46.00 target price on shares of Catalent and gave the company a buy rating in a research note on Monday, December 3rd. TheStreet cut shares of Catalent from a b- rating to a c+ rating in a research note on Wednesday, November 7th. Finally, Robert W. Baird initiated coverage on shares of Catalent in a research note on Thursday, November 15th. They issued an outperform rating on the stock. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock presently has an average rating of Buy and a consensus target price of $47.13.
Catalent (NYSE:CTLT) last issued its quarterly earnings data on Tuesday, February 5th. The company reported $0.45 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.37 by $0.08. The firm had revenue of $623.00 million for the quarter, compared to the consensus estimate of $608.38 million. Catalent had a net margin of 5.48% and a return on equity of 17.42%. Catalent’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same period last year, the firm posted $0.45 EPS. On average, research analysts expect that Catalent will post 1.69 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently made changes to their positions in CTLT. JPMorgan Chase & Co. grew its stake in shares of Catalent by 29.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 7,976,203 shares of the company’s stock worth $363,316,000 after purchasing an additional 1,819,020 shares during the last quarter. Oregon Public Employees Retirement Fund grew its stake in shares of Catalent by 3,074.3% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 1,798,868 shares of the company’s stock worth $58,000 after purchasing an additional 1,742,199 shares during the last quarter. Select Equity Group L.P. acquired a new position in shares of Catalent in the 3rd quarter worth approximately $67,646,000. Vanguard Group Inc grew its stake in shares of Catalent by 9.4% in the 3rd quarter. Vanguard Group Inc now owns 12,925,639 shares of the company’s stock worth $588,763,000 after purchasing an additional 1,110,779 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Catalent by 9.4% in the 3rd quarter. Vanguard Group Inc. now owns 12,925,639 shares of the company’s stock worth $588,763,000 after purchasing an additional 1,110,779 shares during the last quarter. 97.95% of the stock is currently owned by institutional investors.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Further Reading: How Does the Quiet Period Work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.